CryoPort (NASDAQ:CYRX) Stock Crosses Above 200 Day Moving Average – Should You Sell?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $10.07 and traded as high as $16.73. CryoPort shares last traded at $16.16, with a volume of 1,163,706 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have commented on CYRX. BTIG Research raised their price target on shares of CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Needham & Company LLC raised their price target on shares of CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Craig Hallum raised their price objective on shares of CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.31.

CryoPort Stock Performance

The company’s 50-day moving average price is $11.75 and its two-hundred day moving average price is $10.11. The stock has a market cap of $791.28 million, a PE ratio of 11.63 and a beta of 1.90.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. Equities research analysts forecast that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark W. Sawicki sold 3,235 shares of CryoPort stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider owned 103,697 shares in the company, valued at $829,576. This trade represents a 3.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert Stefanovich sold 38,700 shares of CryoPort stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $7.76, for a total transaction of $300,312.00. Following the completion of the transaction, the chief financial officer owned 255,701 shares in the company, valued at approximately $1,984,239.76. The trade was a 13.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,939 shares of company stock worth $471,183 in the last 90 days. 10.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On CryoPort

Large investors have recently added to or reduced their stakes in the business. Basepoint Wealth LLC purchased a new position in CryoPort in the 4th quarter worth $34,000. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. AlphaQuest LLC bought a new stake in CryoPort in the 3rd quarter worth $79,000. Creative Planning bought a new stake in CryoPort in the 2nd quarter worth $96,000. Finally, Quadrature Capital Ltd bought a new stake in CryoPort in the 4th quarter worth $97,000. Hedge funds and other institutional investors own 92.90% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.